San Jose, CA, Aug. 11, 2021– BridGene Biosciences, Inc., a biotechnology company using a unique chemoproteomic technology to discover and develop small molecules for high value, traditionally undruggable targets, announced today the …
BridGene Biosciences Announces Research Collaboration with Takeda to Discover Small Molecule Drugs for “Undruggable” Targets
BridGene Eligible to Receive More Than $500 Million in Potential Upfront and Milestone Payments
Under the terms of the partnership, BridGene will receive from Takeda a one-time upfront payment for access to its IMTACTM technology. For any validated targets selected by Takeda, Takeda will receive an exclusive license to research, develop and commercialize any drug candidates that result from the research programs. BridGene will then be eligible to receive potential preclinical, clinical and commercial milestone payments that could exceed $500 million, as well as royalties from future sales of commercialized drugs resulting from the collaboration.